Currently, both CDK8 and Mcl-1 are being actively pursued as therapeutic targets in breast cancer in general and triple-negative breast cancer specifically [2,15,19,35,36,37,38,39,40,41,42]. This evidence concerns the gene CDK8 and triple-negative breast carcinoma.